Pharmaron Beijing Co., Ltd. (SHE:300759)

Pharmaron Beijing Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	12,269	12,269	11,533	10,240	7,419	5,114
Other Revenue	434.47	6.4	4.61	26.19	24.48	19.55
Revenue	12,704	12,276	11,538	10,266	7,444	5,134
Revenue Growth (YoY)	10.62%	6.39%	12.39%	37.92%	45.00%	36.63%
Cost of Revenue	8,349	8,091	7,422	6,502	4,768	3,215
Gross Profit	4,355	4,184	4,116	3,764	2,676	1,919
Selling, General & Admin	1,855	1,843	1,859	1,728	1,022	745.89
Research & Development	497.86	469.26	448.28	282.32	151.77	105.35
Other Operating Expenses	110.45	109.7	82.75	66.52	44.04	32.9
Operating Expenses	2,511	2,465	2,426	2,098	1,229	898.95
Operating Income	1,844	1,719	1,690	1,667	1,448	1,020
Interest Expense	-217.03	-243.72	-182.19	-167.31	-83.07	-23.85
Interest & Investment Income	551.53	615.7	78.95	109.74	371.99	231.55
Currency Exchange Gain (Loss)	31.43	31.43	147	-42.39	-3.16	-131.23
Other Non Operating Income (Expenses)	3.35	-4.22	-3.61	-2.54	-1.39	-1.35
EBT Excluding Unusual Items	2,213	2,118	1,730	1,564	1,732	1,095
Impairment of Goodwill	-73.54	-73.54	-	-	-	-
Gain (Loss) on Sale of Investments	-24.76	1.54	18.75	68.09	119.59	190.86
Gain (Loss) on Sale of Assets	-13.99	-33.67	-9.15	-15.3	-4.25	-7.28
Asset Writedown	4.32	-	-	-	-	-
Other Unusual Items	81.18	78.51	98.48	49.5	63.73	40.72
Pretax Income	2,186	2,091	1,838	1,666	1,911	1,319
Income Tax Expense	408.34	377.1	256.11	314.25	290.92	172.38
Earnings From Continuing Operations	1,778	1,714	1,582	1,352	1,620	1,147
Minority Interest in Earnings	90.47	79.19	19.32	22.47	40.95	25.39
Net Income	1,868	1,793	1,601	1,375	1,661	1,172
Net Income to Common	1,868	1,793	1,601	1,375	1,661	1,172
Net Income Growth	25.95%	12.01%	16.48%	-17.24%	41.68%	114.25%
Shares Outstanding (Basic)	1,766	1,770	1,772	1,774	1,781	1,779
Shares Outstanding (Diluted)	1,770	1,773	1,775	1,776	1,820	1,785
Shares Change (YoY)	-0.37%	-0.11%	-0.05%	-2.40%	1.97%	20.06%
EPS (Basic)	1.06	1.01	0.90	0.78	0.93	0.66
EPS (Diluted)	1.06	1.01	0.90	0.77	0.91	0.66
EPS Growth	26.42%	12.13%	16.54%	-15.21%	38.94%	78.46%
Free Cash Flow	586.11	536.02	-111.78	-807.04	-34.78	332.77
Free Cash Flow Per Share	0.33	0.30	-0.06	-0.45	-0.02	0.19
Dividend Per Share	0.200	0.200	0.200	0.200	0.200	0.133
Dividend Growth	-	-	-	-	50.04%	99.85%
Gross Margin	34.28%	34.09%	35.67%	36.67%	35.95%	37.38%
Operating Margin	14.51%	14.01%	14.64%	16.23%	19.45%	19.87%
Profit Margin	14.71%	14.61%	13.88%	13.39%	22.31%	22.84%
Free Cash Flow Margin	4.61%	4.37%	-0.97%	-7.86%	-0.47%	6.48%
EBITDA	2,738	2,583	2,431	2,227	1,852	1,325
EBITDA Margin	21.55%	21.04%	21.07%	21.70%	24.88%	25.81%
D&A For EBITDA	893.82	863.3	741.2	560.76	404.64	304.85
EBIT	1,844	1,719	1,690	1,667	1,448	1,020
EBIT Margin	14.51%	14.01%	14.64%	16.23%	19.45%	19.87%
Effective Tax Rate	18.68%	18.03%	13.94%	18.86%	15.22%	13.06%
Revenue as Reported	12,704	12,276	11,538	10,266	7,444	5,134

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.